Thermo Fisher Scientific Oncomine Childhood Cancer Research Assay
Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children's Hospital Los Angeles that specifically targets mutations associated with pediatric and young adult cancers. The assay combines specific mutations, gene amplifications, and fusions over 203 genes representing multiple gene classes, and 1,700 fusion transcripts in two DNA and two RNA pools. The assay is designed to integrate with the Ion Chef system for automated library preparation and amplification, as well as the Ion GeneStudio S5 system and Ion Reporter for bioinformatics and reporting.
Bio-Techne RNAscope Assays
Bio-Techne announced the launch of its RNAscope VS Duplex kit, which delivers simultaneous in situ detection of two RNA species on an automated platform. The assay enables experiments including co-localization studies and gene expression profiling in specific cell types identifiable with known markers. The assay delivers improved specificity and sensitivity with clean signals, allowing researchers to pinpoint gene expression at single-molecule sensitivity.
In addition, Bio-Techne has launched the RNAScope VS Universal HRP and AP assays, which will integrate with Roche's mRNA universal software. The assays also have protocols that allow dual staining with immunohistochemistry or immunofluorescence.
Bio-Techne has also released the updated RNAscope 2.5 VS Reagent Kit-BROWN and -RED assays, which deliver permanent and intensified staining. The firm claims the assays are suitable for archiving and are ideal when anticipating low copy target gene expression.
Mission Bio Tapestri, Panels
Mission Bio has updated its Tapestri single-cell DNA analysis platform, which is now compatible with the Illumina HiSeq 2500 sequencer to allow for multiplexing and larger panels.
The company has also launched two new panels for myeloid disorders and for solid tumor profiling. The Tapestri Single-Cell DNA Myeloid Panel, designed to cover several myeloid disorders, targets single-nucleotide variants and indels in 47 genes. The Tapestri Single-Cell Tumor Hotspot Panel targets SNV and indel hotspot mutations across 50 genes involved in different solid tumor types and has been tested with breast, lung, prostate, and colorectal cancer nuclei from fresh-frozen tissue samples.
For more new products and services, please visit the New Products page on our website.